Tanja Ruokoranta

5PUBLICATIONS
32CO-AUTHORS
Gene and molecular therapyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 01, 2026
Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

|Jan 14, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Ida Vänttinen, Joseph Saad, Tanja Ruokoranta

|May 12, 2025
A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

Yingjia Chen, Liye He, Aleksandr Ianevski

|Oct 03, 2024
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.

Aleksandr Ianevski, Kristen Nader, Kyriaki Driva

|Oct 02, 2024
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta

Pageof 1

Frequent Collaborators

4 joint publications

Ida Vänttinen

4 joint publications

Caroline A Heckman

3 joint publications

Kimmo Porkka

3 joint publications

Heikki Kuusanmäki